Jerry D. Gardner

Jerry D. Gardner's AcademicInfluence.com Rankings

Jerry D. Gardner

Medical

#1881

World Rank

#2262

Historical Rank

Pharmacology

#182

World Rank

#221

Historical Rank

medical Degrees

Download Badge

Medical

Jerry D. Gardner's Degrees

PhD Pharmacology University of California, San Francisco
Bachelors Chemistry University of California, Berkeley

Why Is Jerry D. Gardner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jerry D. Gardner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. (1981) (237)
Intraoperative Ultrasonographic Localization of Islet Cell Tumors: A Prospective Comparison to Palpation (1988) (233)
Interactions of COOH-terminal fragments of cholecystokinin with receptors on dispersed acini from guinea pig pancreas. (1982) (216)
Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells. (1980) (209)
Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells. (1978) (207)
Zollinger-Ellison syndrome: current concepts and management. (1983) (196)
Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. (1976) (193)
Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Binding of radioiodinated peptide. (1976) (189)
Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. (1985) (187)
Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. (1989) (185)
Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. (1988) (183)
Regulation of amylase release from dispersed pancreatic acinar cells. (1977) (173)
Interaction of CCK with pancreatic acinar cells. (1989) (172)
Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. (1985) (166)
Kinetics of amylase release by dispersed acini prepared from guinea pig pancreas. (1978) (161)
A synthetic peptide that is a bombesin receptor antagonist (1984) (159)
Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. (1987) (155)
Prospective Study of Gastrinoma Localization and Resection in Patients with Zollinger‐Ellison Syndrome (1986) (151)
Cushing's syndrome in patients with the Zollinger-Ellison syndrome. (1986) (149)
Actions of derivatives of cyclic nucleotides on dispersed acini from guinea pig pancreas. Discovery of a competitive antagonist of the action of cholecystokinin. (1979) (148)
Aggressive Resection of Metastatic Disease in Selected Patients with Malignant Gastrinoma (1986) (145)
Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. (1989) (142)
Action of cholecystokinin and cholinergic agents on calcium transport in isolated pancreatic acinar cells. (1975) (142)
Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. (1989) (141)
Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. (1988) (140)
Reflux esophagitis in patients with Zollinger-Ellison syndrome. (1990) (128)
Regulation of pancreatic exocrine function in vitro: initial steps in the actions of secretagogues. (1979) (128)
Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. (1983) (125)
Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors. (1989) (124)
Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. (1990) (124)
Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. (1985) (123)
Action of cholecystokinin, cholinergic agents, and A-23187 on accumulation of guanosine 3':5'-monophosphate in dispersed guinea pig pancreatic acinar cells. (1976) (122)
Gastrinomas: localization by means of selective intraarterial injection of secretin. (1990) (118)
Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. (1983) (114)
Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. (1987) (113)
Viral gastroenteritis induced by the Hawaii agent. Jejunal histopathology and serologic response. (1975) (109)
Prospective study of chemotherapy in patients with metastatic gastrinoma. (1988) (108)
Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. (1987) (105)
Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. (1984) (101)
The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. (1990) (99)
Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling. (1984) (99)
Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. (1988) (98)
The Effects of Sodium and Potassium on Ouabain Binding by Human Erythrocytes (1972) (97)
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. (1992) (96)
Gastric emptying and secretion in Zollinger-Ellison syndrome. (1977) (92)
Effects of vasoactive intestinal peptide, secretin, and related peptides on rat colonic transport and adenylate cyclase activity. (1977) (91)
Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. (1989) (89)
Cholecystokinin-27-32-amide. A member of a new class of cholecystokinin receptor antagonists. (1983) (87)
Pancreatic cholera: benefical effects of treatment with streptozotocin. (1975) (84)
Selective venous sampling for gastrin to localize gastrinomas. A prospective assessment. (1986) (83)
Insulin action in isolated rat thymocytes. I. Binding of 125 I-insulin and stimulation of -aminoisobutyric acid transport. (1972) (83)
Receptor occupation, calcium mobilization, and amylase release in pancreatic acini: effect of CCK-JMV-180. (1989) (78)
Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. (2002) (76)
CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors. (1989) (76)
Cyclic AMP in pancreatic acinar cells: effects of gastrointestinal hormones. (1976) (73)
Receptors for vasoactive intestinal peptide and secretin on rat pancreatic acini. (1984) (73)
Importance of sulfation of gastrin or cholecystokinin (CCK) on affinity for gastrin and CCK receptors (1989) (68)
H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy. (1977) (68)
Effect of β-Adrenergic Catecholamines on Sodium Transport in Turkey Erythrocytes (1973) (68)
Alterations of in vitro fluid and electrolyte absorption by gastrointestinal hormones. (1967) (67)
Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors (1989) (66)
Interaction of Bombesin and Related Peptides with Receptors on Pancreatic Acinar Cells (1988) (66)
Pepsinogen secretion from dispersed chief cells from guinea pig stomach. (1984) (64)
Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists. (1989) (64)
Cholecystokinin (pancreozymin). 4. Synthesis and properties of a biologically active analogue of the C-terminal heptapeptide with epsilon-hydroxynorleucine sulfate replacing tyrosine sulfate. (1978) (62)
[D-Phe12]bombesin analogues: a new class of bombesin receptor antagonists. (1987) (61)
Characterization of gastrin receptors on guinea pig pancreatic acini. (1987) (61)
Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. (1984) (59)
Effects of gastrointestinal hormones on adenylate cyclase activity in human jejunal mucosa. (1975) (58)
Mechanism of [Tyr4]bombesin-induced desensitization in dispersed acini from guinea pig pancreas. (1982) (57)
Interaction of physalaemin, substance P, and eledoisin with specific membrane receptors on pancreatic acinar cells. (1979) (57)
Cholecystokinin-induced formation of inositol phosphates in pancreatic acini. (1990) (57)
Multiple affinity states of different cholecystokinin receptors. (1994) (56)
Effects of interleukin-6 on fetal hematopoietic progenitors. (1990) (56)
Cholecystokinin receptor antagonists. (1984) (55)
Altered membrane sodium transport in Bartter's syndrome. (1972) (54)
Structural features of various proglumide-related cholecystokinin receptor antagonists. (1986) (52)
Interaction of secretin5-27 and its analogues with hormone receptors on pancreatic acini. (1979) (51)
[Cholecystokinin-pancreozymin synthesis. Synthesis of [28-threonine,31-norleucine]- and [28-threonine,31-leucine]cholecystokinin-pancreozymin-(25-33)-nonapeptide]. (1981) (50)
Characterization of receptors for calcitonin gene-related peptide on gastric smooth muscle cells. (1988) (50)
Pancreatic receptors for cholecystokinin: evidence for three receptor classes. (1990) (50)
Interaction of substance P antagonists with substance P receptors on dispersed pancreatic acini. (1984) (49)
Actions of Gila monster venom on dispersed acini from guinea pig pancreas. (1982) (49)
Cholecystokinin receptors on gallbladder muscle and pancreatic acinar cells: a comparative study. (1988) (48)
Effects of alcohols on the actions of VIP and secretin on acinar cells from guinea pig pancreas. (1979) (48)
Effects of cholecystokinin (CCK) and other secretagogues on isoforms of protein kinase C (PKC) in pancreatic acini. (1994) (48)
Direct demonstration of three different states of the pancreatic cholecystokinin receptor. (1994) (48)
Cellular cyclic AMP in dispersed mucosal cells from guinea pig stomach. (1978) (48)
Receptors for vasoactive intestinal peptide and secretin on small intestinal epithelial cells. (1980) (48)
Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes. (1973) (47)
Cellular distribution of isoforms of protein kinase C (PKC) in pancreatic acini. (1995) (47)
Famotidine in the therapy of gastric hypersecretory states. (1986) (47)
Cholecystokinin (pancreozymin). 3. Synthesis and properties of an analogue of the C-terminal heptapeptide with serine sulfate replacing tyrosine sulfate. (1977) (47)
Inhibition of parietal cell function by human gammaglobulin containing gastric parietal cell antibodies. (1980) (47)
Cholecystokinin-induced contraction of dispersed smooth muscle cells. (1982) (46)
Abnormal membrane sodium transport in Liddle's syndrome. (1971) (45)
Structural requirements for action of cholecystokinin on enzyme secretion from pancreatic acini. (1982) (44)
Actions of a newly isolated intestinal peptide PHI on pancreatic acini. (1981) (44)
Proglumide analogues: potent cholecystokinin receptor antagonists. (1985) (43)
Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. (1990) (43)
Receptors and cell activation associated with pancreatic enzyme secretion. (1986) (42)
Postreceptor modulation of action of VIP and secretin on pancreatic enzyme secretion by secretagogues that mobilize cellular calcium. (1982) (42)
Regulation of pancreatic exocrine secretion in vitro: the action of secretagogues. (1981) (41)
Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. (1989) (41)
Receptor for secretagogues on pancreatic acinar cells. (1980) (41)
Famotidine: effective treatment of Zollinger-Ellison syndrome. (1987) (41)
Cholecystokinin-induced desensitization of enzyme secretion in dispersed acini from guinea pig pancreas. (1980) (40)
Receptors for secretagogues on pancreatic acinar cells. (1984) (39)
Transport of dibasic amino acids by human erythrocytes. (1972) (39)
Mechanism of action of calcitonin gene-related peptide in stimulating pancreatic enzyme secretion. (1986) (39)
Use of 125I-secretin to identify and characterize high-affinity secretin receptors on pancreatic acini. (1983) (39)
Receptors for gastrointestinal hormones. (1979) (37)
Gastric emptying and secretion in the rhesus monkey. (1977) (37)
Multiple hormone elevations in Zollinger-Ellison syndrome: Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome (1990) (37)
Sequence of events mediating the effect of cholera toxin on rat thymocytes. (1974) (36)
Effect of substitutions in position 12 of bombesin on antagonist activity (1989) (36)
Cyclic nucleotide-dependent protein kinase activity in acinar cells from guinea pig pancreas. (1978) (36)
Integrated acidity and rabeprazole pharmacology (2002) (36)
Potentiation of pepsinogen secretion from dispersed glands from rat stomach. (1983) (36)
Ovarian Carcinoma as a Cause of Zollinger-Ellison Syndrome Natural History, Secretory Products, and Response to Provocative Tests (1989) (35)
Thapsigargin defines the roles of cellular calcium in secretagogue-stimulated enzyme secretion from pancreatic acini. (1992) (35)
Identification and characterization of receptors for secretagogues on pancreatic acinar cells. (1981) (35)
COOH-terminal fragments of cholecystokinin. A new class of cholecystokinin receptor antagonists. (1983) (34)
Beneficial effect of oral lithium carbonate in the treatment of pancreatic cholera syndrome. (1980) (34)
Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. (1991) (34)
Properties of receptors for gastrin and CCK on gastric smooth muscle cells. (1989) (34)
A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. (1988) (34)
Interaction of peptides related to secretin with hormone receptors on pancreatic acinar cells. (1976) (33)
Effects of beta-adrenergic catecholamines on potassium transport in turkey erythrocytes. (1975) (33)
Actions of peptides isolated from amphibian skin on pancreatic acinar cells. (1978) (32)
Effects of cholecystokinin on adenylate cyclase activity in dispersed pancreatic acinar cells. (1977) (32)
Characterization of cholinergic receptors mediating pepsinogen secretion from chief cells. (1989) (31)
Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. (1989) (31)
Effect of extracellular manganese on amylase release from dispersed pancreatic acini. (1979) (31)
Reversal of the pharmacological and toxic effects of cardiac glycosides by specific antibodies. (1973) (31)
Solid-phase synthesis of porcine vasoactive intestinal peptide. (2009) (31)
Jejunal adenylate cyclase activity in human subjects during viral gastroenteritis. (1976) (31)
Interaction of synthetic 10-tyrosyl analogues of secretin with hormone receptors on pancreatic acinar cells. (1977) (31)
Functionally distinct receptors for cholecystokinin and gastrin on dispersed chief cells from guinea pig stomach. (1988) (30)
Receptors for vasoactive intestinal peptide and secretin on guinea pig pancreatic acini (1987) (29)
Beta-adrenergic receptors, cyclic AMP, and ion transport in the avian erythrocyte. (1975) (29)
Down-regulation and recycling of high affinity cholecystokinin receptors on pancreatic acinar cells. (1991) (28)
Evidence against cyclic GMP as a mediator of the actions of secretagogues on amylase release from guinea-pig pancreas. (1980) (28)
Interaction of peptides related to VIP and secretin with guinea pig pancreatic acini. (1989) (28)
Action of natural glucagon on pancreatic acini: due to contamination by previously undescribed secretagogues. (1983) (27)
Characterization of ability of various substance P antagonists to inhibit action of bombesin. (1988) (27)
Action of cholera toxin on dispersed acini from guinea pig pancreas. (1979) (27)
Cholecystokinin (pancreozymin). Synthesis and properties of the N alpha-acetyl-derivative of cholecystokinin 27-33. (2009) (27)
Direct determination of ligand interactions with beta-adrenergic receptors on intact turkey erythrocytes: correlation of binding with biological activity. (1976) (27)
Secretagogue-induced membrane alterations in dispersed acini from rat pancreas. (1984) (27)
Effects of extracellular cations and ouabain on catecholamine-stimulated sodium and potassium fluxes in turkey erythrocytes. (1975) (26)
Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. (1994) (26)
Integrated acidity and the pathophysiology of gastroesophageal reflux disease. (2001) (26)
Action of cholecystokinin and cholinergic agents on membrane-bound calcium in dispersed pancreatic acinar cells. (1976) (26)
Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome (1993) (26)
Potential mechanisms of interaction among secretagogues (1978) (25)
Calcium-activated, phospholipid-dependent protein kinase in pancreatic acinar cells. (1985) (25)
Actions of vasoactive intestinal peptide and secretin on chief cells prepared from guinea pig stomach. (1986) (25)
Activities of calcitonin gene-related peptide (CGRP) and related peptides at the CGRP receptor (1990) (25)
Diagnosis and management of Zollinger-Ellison syndrome. (1989) (24)
Hyperhistaminemia and hyperchlorhydria in basophilic granulocytic leukemia. (1976) (24)
Pepsinogen secretion from dispersed glands from rabbit stomach. (1983) (24)
Bombesin-induced desensitization of enzyme secretion in dispersed acini from guinea pig pancreas. (1980) (24)
Action of histamine on cyclic AMP in guinea pig gastric cells: inhibition by H1- and H2-receptor antagonists. (1979) (23)
Cyclic nucleotide antagonists of cholecystokinin: structural requirements for interaction with the cholecystokinin receptor. (1982) (23)
The columnar epithelial cell of the small intestine: digestion and transport. 3. (1970) (23)
Reduced peptide bond pseudopeptide analogues of substance P. A new class of substance P receptor antagonists with enhanced specificity. (1989) (23)
Diagnosis and management of the Zollinger-Ellison syndrome. (1989) (22)
The importance of the amino acid in position 27 of cholecystokinin in determining its biological activity on pancreatic acini. (1980) (22)
Receptor function and ion transport in turkey erythrocytes. (1976) (22)
Integrated acidity and the pathophysiology of gastroesophageal reflux disease (2001) (22)
Mechanism of action of ATP on intestinal epithelial cells. Cyclic AMP-mediated stimulation of active ion transport. (1982) (21)
Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. (1990) (21)
The columnar epithelial cell of the small intestine: digestion and transport. (First of three parts). (1970) (21)
Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome. (1992) (21)
Gastrointestinal peptides: the basis of action at the cellular level. (1983) (21)
Receptor antagonists for gastrointestinal peptides. (1993) (20)
The importance of the amino acid in position 32 of cholecystokinin in determining its interaction with cholecystokinin receptors on pancreatic acini. (1981) (19)
Structure-function studies of N-acyl derivatives of tryptophan that function as specific cholecystokinin receptor antagonists. (1983) (19)
Zollinger-Ellison syndrome. Recent advances in the management of the gastrinoma. (1990) (19)
Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome. (1989) (19)
Carbachol Does Not Down‐Regulate Substance P Receptors in Pancreatic Acini (1992) (19)
Persistent constipation and abdominal adverse events with newer treatments for constipation (2016) (18)
Potassium transport in dispersed mucosal cells from guinea pig stomach. (1978) (18)
Calcium transport in dispersed acinar cells from rat pancreas. (1977) (18)
An analogue of substance P with broad receptor antagonist activity. (1988) (18)
Characterization of the bombesin receptor on mouse pancreatic acini by chemical cross-linking (1990) (18)
Synergy between low‐dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal‐induced heartburn (2001) (18)
Actions of peptides isolated from amphibian skin on amylase release from dispersed pancreatic acini. (1979) (17)
Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome. (1987) (17)
Bombesin-induced residual stimulation of amylase release from mouse pancreatic acini. (1985) (17)
Peptic ulcer perforation as the presentation of Zollinger-Ellison syndrome (2005) (17)
8 – Cholecystokinin Receptor Antagonists: Ability to Distinguish Various Classes of Cholecystokinin Receptors (1990) (17)
Cholecystokinin-induced persistent stimulation of enzyme secretion from pancreatic acini. (1981) (17)
Post-reflux swallow-induced peristaltic wave (PSPW): physiology, triggering factors and role in reflux clearance in healthy subjects (2020) (17)
Cyclic GMP does not inhibit protein kinase C-mediated enzyme secretion in rat pancreatic acini. (1989) (16)
Binding of 125I-CCK-8 and 125I-gastrin-I to dispersed chief cells from guinea-pig stomach. (1990) (16)
Characterization of receptors for VIP on pancreatic acinar cell plasma membranes using covalent cross-linking. (1987) (16)
Synthesis and some pharmacological properties of the 23-peptide 15-lysine-secretin-(5--27). Special role of the residue in position 15 in biological activity of the vasoactive intestinal polypeptide. (1978) (16)
Control of Nocturnal Gastric Acidity: A Role for Low Dose Bedtime Ranitidine to Supplement Daily Omeprazole (2002) (16)
Cholecystokinin-induced restricted stimulation of pancreatic enzyme secretion. (1982) (16)
Carbobenzoxy amino acids: structural requirements for cholecystokinin receptor antagonist activity. (1985) (16)
In vitro Inhibition of Intestinal Fluid and Electrolyte Transfer by a Non-Beta Islet Cell Tumor (1966) (16)
Effect of cholecystokinin variant (CCK39) on dispersed acinar cells from guinea pig pancreas. (1977) (16)
Low mannitol clearance into cholera stool as evidence against filtration as the source of stool fluid. (1972) (15)
Effects of ouabain on catecholamine-stimulated sodium transport in turkey erythrocytes. (1974) (15)
Ouabain binding and cation transport in human erythrocytes. (1973) (15)
Impaired renal tubular secretion of potassium, elevated sweat sodium chloride concentration and plasma inhibition of erythrocyte sodium outflux as complications of systemic lupus erythematosus. (1972) (15)
Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. (1994) (15)
Effect of extracellular calcium on amylase release from dispersed pancreatic acini. (1979) (15)
Characterization of cholecystokinin receptors on the sphincter of Oddi. (1990) (15)
Dispersed pancreatic acinar cells and pancreatic acini. (1990) (15)
Cholecystokinin (pancreozymin). 5. Hormonally active desamino derivative of Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2. (1980) (14)
Modulation of cholecystokinin activity by albumin. (1995) (14)
Frequency analyses of gastric pH in control and gastro‐oesophageal reflux disease subjects treated with a proton‐pump inhibitor (2004) (14)
Successful Therapy of Pancreatic Cholera with the Long-Acting Somatostatin Analogue SMS 201-995: Relation between Plasma Concentrations of Drug and Clinical and Biochemical Responses (1986) (14)
Occupation of low-affinity cholecystokinin (CCK) receptors by CCK activates signal transduction and stimulates amylase secretion in pancreatic acinar cells. (1993) (14)
Kinetics of binding of cholecystokinin to pancreatic acini. (1988) (14)
Gastrin and colon cancer: a unifying hypothesis. (1996) (13)
Amino acid transport in isolated rat thymocytes. Effects of divalent cations and ethanol. (1976) (12)
Abnormal Erythrocyte Sodium Transport in Cystic Fibrosis of the Pancreas (1971) (12)
Stimulation of sodium transport in turkey erythrocytes by cyclic 3',5'-AMP. (1974) (12)
Effects of inhibitors of cyclic nucleotide phosphodiesterase on actions of cholecystokinin, bombesin, and carbachol on pancreatic acini. (1983) (12)
Synthesis and some pharmacological properties of Z-Tyr(SO3H)-Met-Gly-Trp-Met-Asp(Phe-NH2)-OH, a 32-beta-aspartyl analogue of cholecystokinin (pancreozymin) 27-33. (1982) (12)
Refractoriness of cation transport in turkey erythrocytes to stimulation by cyclic adenosine 3':5'-monophosphate. (1975) (11)
Mycobacterium fortuitum infection: evidence of bactericidal defect due to hyperactive antigen-specific suppressor cells. Correction in vitro and in vivo by cholinergic agonist and indomethacin. (1982) (11)
Action of theophylline on secretagogue-stimulated amylase release from dispersed pancreatic acini. (1980) (11)
Ovarian carcinoma as a cause of Zollinger-Ellison syndrome. Natural history, secretory products, and response to provocative tests. (1989) (11)
Cholecystokinin (CCK)-induced desensitization of pancreatic enzyme secretion is mediated by low affinity CCK receptors (1989) (11)
Dental identification of remains from the 23 October 1983 bombing of the U.S. Marine Headquarters, Beirut, Lebanon. (1985) (11)
PRODUCTION AND PROPERTIES OF DIGOXIN‐SPECIFIC ANTIBODIES * (1974) (11)
Regulation of bombesin receptors on pancreatic acini by cholecystokinin. (1989) (11)
Gastrointestinal peptides and cancer (1993) (10)
In vitro growth of epithelial cells from mucosa derived from different regions of the gastrointestinal tract (1987) (10)
Integrated gastric acidity can predict the prevention of naproxen-induced gastroduodenal pathology in normal subjects (2003) (10)
Derivatives of CCK-(26-32) as cholecystokinin receptor antagonists in guinea pig pancreatic acini. (1984) (10)
Cholecystokinin Receptor Antagonists In Vitro (1991) (10)
Increased jejunal IgA synthesisin vitro during acute infectious nonbacterial gastroenteritis (1974) (10)
Interaction of tryptophan-modified analogues of cholecystokinin-octapeptide with cholecystokinin receptors on pancreatic acini. (1981) (9)
Actions of natural gastric inhibitory peptide on pancreatic acinar cells: due to contamination with cholecystokinin. (1982) (9)
Cell membrane receptors for secretagogues on pancreatic acinar cells (1988) (9)
Effect of A23187 on amylase release from dispersed acini prepared from guinea pig pancreas. (1980) (9)
Reversal of cholecystokinin-induced persistent stimulation of pancreatic enzyme secretion by dibutyryl cyclic GMP. (1981) (9)
Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase. (1986) (8)
Sodium transport in human erythrocytes--absence of an effect of prostaglandin E1. (1971) (8)
Discovery of a cholecystokinin analogue with partial agonist activity. (1984) (8)
Action of VIP and secretin on adenylate cyclase activity in acinar cells from guinea pig pancreas. (1979) (8)
Effects of calcium and chelating agents on the ability of various agonists to increase cyclic GMP in pancreatic acinar cells. (1978) (8)
Carbachol desensitizes pancreatic enzyme secretion by downregulation of receptors. (1990) (8)
Effects of inhibitors of cyclic nucleotide phosphodiesterase on the actions of vasoactive intestinal peptide and secretin on pancreatic acini. (1982) (8)
Follow-up of a patient with somatostatinoma. (1986) (7)
Role of sulfate ester in influencing biologic activity of cholecystokinin-related peptides. (1987) (7)
Effects of saliva and plasma from cystic fibrosis patients on membrane transport. (1972) (7)
Action of cholera toxin on dispersed acini from rat pancreas. Post-receptor modulation involving cyclic AMP and calcium. (1982) (7)
Diagnosis and Management of the Zollinger‐Ellison Syndrome (1983) (7)
Effect of inhibition of microsomal Ca(2+)-ATPase on cytoplasmic calcium and enzyme secretion in pancreatic acini. (1994) (7)
Direct Identification and Characterization of β-Adrenergic Receptors and Functional Relationship of Adenylyl Cyclase (1978) (6)
Receptor identification. (1990) (6)
[35] Receptor identification (1990) (6)
Mechanism by which dibutyryl cyclic guanosine monophosphate antagonizes the action of cholecystokinin. (1983) (6)
Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors (2008) (6)
Abnormal Erythrocyte Sodium Transport in Cystic Fibrosis (CF) (1970) (6)
Effects of cations on ouabain binding by intact human erythrocytes (2005) (6)
Characterization of receptors for gastrointestinal peptides. (1983) (5)
Potential mechanisms of interaction among secretagogues. (1978) (5)
Heartburn severity can predict pathologic oesophageal reflux in gastro‐oesophageal reflux disease patients treated with a proton‐pump inhibitor (2003) (5)
Stimulation of secretion by secretagogues. (1990) (5)
Cholecystokinin-induced residual stimulation of enzyme secretion from mouse pancreatic acini. (1987) (5)
Plasma VIP in patients with watery diarrhea syndrome (1978) (5)
Effect of beta-adrenergic catecholamines on sodium transport in turkey erythrocytes. (1973) (5)
Effect of temperature on sodium transport in human erythrocytes in vitro. (1971) (5)
Omeprazole: An Effective Drug for Zollinger-Ellison Syndrome (1986) (5)
N-terminal fragments of CCK-(26-33) as cholecystokinin receptor antagonists in guinea pig pancreatic acini. (1985) (5)
Effect of Verapamil on the Cyclic AMP‐Mediated Pathway for Amylase Secretion in Rat Pancreatic Acini (1993) (4)
GERD: Increased gastric acid secretion as a possible cause of GERD (2010) (4)
The cytochemical section-bioassay of gastrin-like activity. (1980) (4)
Characterization of a Persistent Inhibitory Action of L‐364,718 on Cholecystokinin‐Stimulated Enzyme Secretion in Pancreatic Acini (1994) (4)
Preparation of dispersed pancreatic acinar cells and dispersed pancreatic acini. (1985) (4)
In GERD patients taking a morning dose of omeprazole, bedtime low-dose ranitidine is equivalent to bedtime omeprazole for inhibition of nocturnal gastric acidity (2000) (4)
Takayasu's arteritis: reversal of pulse deficit after early treatment with corticosteroids. (1984) (4)
A two-site model for sodium transport in rabbit erythrocytes. (1971) (4)
GERD Subjects with Increased Nocturnal Esophageal Acidity Have Increased Nocturnal Gastric Acidity: 4 (2005) (4)
Zollinger-Ellison Syndrome in the Intensive Care Setting (1989) (4)
Bombesin receptor antagonists. 2. Analogues based on substance P antagonists. (1991) (4)
Biochemical basis of action of gastrointestinal hormones (1979) (3)
Sodium outflux and ATPase activity in human and rabbit erythrocytes. (1971) (3)
Zollinger-Ellison Syndrome: Advances in Diagnosis and Management (1991) (3)
Comparison of Famotidine with Ranitidine and Cimetidine in the Treatment of Zollinger-Ellison Syndrome (1985) (3)
The actions of tetraethylammonium on dispersed acini from guinea pig pancreas. (1983) (3)
Carbachol-induced down-regulation of high-affinity receptors for vasoactive intestinal peptide. (1989) (3)
Maximal or near-maximal inhibition of esophageal acidity by the 1st dose of rabeprazole in GERD (2000) (2)
A newly recognized action of cholecystokinin on pancreatic acini-release of lactate dehydrogenase. (1993) (2)
American gastroenterological association american association for the study of liver diseases gastroenterology research group New York city, May 18–20, 1981 (2007) (2)
Exploring the physiologic role of human gastroesophageal reflux by analyzing time‐series data from 24‐h gastric and esophageal pH recordings (2014) (2)
Endoscopy-negative GERD is a gastric ‘hypersecretory’ disorder (2000) (2)
Insulin Action in Isolated Rat Thymocytes (2003) (2)
Selective modification of the ability of cholecystokinin to cause residual stimulation of pancreatic enzyme secretion. (1982) (2)
Determination of onset, duration of action and maximal effect of rabeprazole on gastric and esophageal acidity in GERD (2000) (2)
The relationship between esophageal acidity and symptom frequency in symptomatic nonerosive gastroesophageal reflux disease (2022) (2)
Letter: Gastric emptying. (1974) (2)
How do I interpret a positive diagnostic test? (2007) (2)
Tu1105 Attributable Risk - Interpreting Side Effects in Clinical Trials of Newer Treatments for Constipation at the Level of the Individual Patient (2016) (2)
SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF THE 23-PEPTIDE 15-LYSINE-SECRETIN-(5-27). SPECIAL ROLE OF THE RESIDUE IN POSITION 15 IN BIOLOGICAL ACTIVITY OF THE VASOACTIVE INTESTINAL POLYPEPTIDE (1979) (2)
Timing and Outcomes of Endoscopy for esophageal Food Bolus Impaction (2022) (1)
A two-site model for sodium transport in human erythrocytes. (1971) (1)
Assay for the cholecystokinin receptor on pancreatic acini. (1985) (1)
Cibacron blue-induced enhancement of agonist binding to cholecystokinin (CCK) receptors in solubilized pancreatic membranes. (1993) (1)
The cellular basis of action of gastrointestinal peptides. (1984) (1)
Diagnostic Performance of Esophageal pH Electrodes at Different Locations (2009) (1)
The importance of calcium for the regulation of cyclic guanosine 3': 5'-monophosphate levels by pancreozymin, carbamoylcholine and ionophore A-23187 in isolated pancreatic acinar cells. (1975) (1)
Prospective Assessment of the Safety and Efficacy of Long-term Omeprazole Therapy in Patients with Zollinger-Ellison Syndrome (1989) (1)
COLORECTAL CANCER PREVENTION (2007) (1)
Importance of the amino acid in position 15 of VIP and secretin in influencing their interactions with membrane receptors on pancreatic acinar cells. (1980) (1)
Structure-Function Studies of Agonists and Antagonists for Gastrointestinal Peptide Receptors on Pancreatic Acinar Cells (1986) (1)
Current Management of Zollinger-Ellison Syndrome (1986) (1)
Carbachol-induced down-regulation of receptors for pancreatic secretagogues. (1990) (1)
Receptors for Gut Peptides and Other Secretagogues on Pancreatic Acinar Cells (2011) (1)
[Studies on the total synthesis of cholecystokinin-pancreozymin. Synthesis of the suitably protected fragment corresponding to the sequence 24--33 (author's transl)]. (1981) (1)
Characterization of bombesin-receptors on dispersed guinea pig pancreatic acini (1987) (1)
Cholecystokinin antagonists. (1986) (1)
Direct neutralization of esophageal acid by antacid in meal-induced heartburn (2000) (1)
Receptor modulation of calcium and cyclic AMP: differences in coupling to specific hormone-receptor complexes in cells responsive to several hormones. (1982) (1)
Role of gastric acid in esophageal acid reflux (2001) (0)
Subject Index, Vol. 46, Supplement 2, 1990 (1990) (0)
In vivo gastric autotitration: a novel, simple method to measure meal-stimulated gastric acid secretion (2001) (0)
Identification of a novel, beneficial action of proton pump inhibitors in GERD (2000) (0)
Nocturnal Gastric Alkalinization in Healthy Human Subjects: 119 (2009) (0)
Gastrointestinal abnormalities in systemic mastocytosis (1985) (0)
Contents, Vol. 14, 1996 (1992) (0)
M1856 Continuous Distal Esophageal Acidification Reduces Postprandial Gastric Acidity in Healthy Human Subjects (2009) (0)
Specific Binding and Ability of Vasoactive Intestinal Octacosa-Peptide (VIP) to Activate Adenylate Cyclase in Isolated Pancreatic Acinar Cells from the Guinea Pig (1976) (0)
SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF Z-TYR(SO3H)-MET-GLY-TRP-MET-ASP(PHE-NH2)-OH, A 32-β-ASPARTYL ANALOG OF CHOLECYSTOKININ (PANCREOZYMIN)-27-33 (1982) (0)
Clinicians and FDA Decisions (2008) (0)
The columnar epithelial cell of the small intestine: digestion and transport. II. (1970) (0)
Precise quantitation of nocturnal esophageal reflux in healthy subjects (2001) (0)
Pancreatic acini as second messenger models in exocrine secretion. (1989) (0)
by in vivo gastric autotitration Measurement of meal-stimulated gastric acid secretion (2015) (0)
Relationship between esophageal acid exposure and heartburn severity in meal-lnduced heartburn (2000) (0)
1 – Role of Receptors in Expression of Gastrointestinal Hormone Function (1990) (0)
Oesophageal pH has a power‐law distribution in control and gastro‐oesophageal reflux disease subjects. (2005) (0)
Meal-induced heartburn: Quantification of esophageal acid exposure and its relationship to gastric acidity (2000) (0)
Su1657 IN AN INDIVIDUAL WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH OBETICHOLIC ACID, THE PROBABILITY OF PRURITUS IS HIGHER THAN THAT OF A CLINICAL RESPONSE, BUT PRURITUS IS LESS LIKELY TO BE ATTRIBUTABLE TO THE DRUG. (2020) (0)
Actions of cck jmv 180 on amylase secretion and release of lactic dehydrogenase ldh from pancreatic acini (1991) (0)
Measurement of meal-stimulated gastric acid secretion and exophageal pH in ambulatory subjects who ingest typical meals (2001) (0)
Characterization of the abnormality in esophageal acid exposure in gastroesophageal reflux disease (2002) (0)
CLINICAL VIGNETTES (2020) (0)
Inhibition of Gastrin-Responsiveness by Parietal Cell Antibodies (1979) (0)
Su1070 Development of a Mobile Phone Application to Diagnose GERD (2012) (0)
Heartburn severity can predict the presence of pathologic esophageal reflux in patients with GERD (2003) (0)
Attributable Benefit -- Interpreting Results from Clinical Trials of Newer Treatments for Constipation at the Level of the Individual Patient (2017) (0)
How do provocative meals cause heartburn? Integrated gastric acidity as the determinant of esophageal acid exposure (2000) (0)
The Information Content of Esophageal pH Values in Vulcan Syndrome Differs from That in Normal and GERD Subjects: 20 (2006) (0)
RECEPTOR ANTAGONISTS OF THE ACTIONS OF GASTROINTESTINAL PEPTIDES ON PANCREATIC ACINAR CELLS (1982) (0)
Fasting gastric pH can predict the likelihood of pathologic esophageal reflux in gerd patients treated with a proton pump inhibitor (2003) (0)
Measures of Effect Size Can Avoid Dependence of Odds Ratio and Relative Risk on the Control Response (2011) (0)
Measures of Effect Size Provide Clinically Relevant Information Regarding the Beneficial Effects PN 400 on Naproxen-Induced Endoscopic Gastric Ulcers (2011) (0)
Meal-stimulated gastric acid secretion in healthy subjects correlates with postprandial but not fasting gastric acidity (2001) (0)
Functional Heartburn in a Non-Disease: 21 (2006) (0)
Subject Index Vol. 14, 1996 (1996) (0)
Esophageal acid sensitivity modulates response to acid reducing therapy in postprandial heartburn (2000) (0)
Relationships Between Inhibition of Gastric and Esophageal Acidity in GERD Patients Being Treated with a Proton Pump Inhibitor: 31 (2008) (0)
Missed opportunity in Zollinger-Ellison syndrome research. (2013) (0)
1018 A Questionable Investment for Our Patients: Challenging the Efficacy of New Therapies for Opioid-Induced and Chronic Idiopathic Constipation (2015) (0)
Heartburn frequency can predict the presence of pathologic esophageal reflux in GERD patients without esophagitis during treatment with rabeprazole (2003) (0)
News and notices (2005) (0)
Increased postprandial gastric acidity is a major pathophysiologic abnormality in gastroesophageal reflux disease (2002) (0)
Sa1075 Measures of Effect Size Provide Clinically Relevant Information Regarding the Beneficial Effects of Telaprevir in Hepatitis C (2012) (0)
Title: IDENTIFYING DIFFERENT PHENOTYPES OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE USING ARTIFICIAL INTELLIGENCE Running Title: ARTIFICIAL INTELLIGENCE AND GASTROESOPHAGEAL REFLUX DISEASE (2023) (0)
The Vulcan Syndrome – Asymptomatic Healthy Volunteers with Pathologic Esophageal Acid Exposure: 3 (2005) (0)
Cholecystokinin receptor-mediated changes in cellular calcium transport (1983) (0)
Subject Index, Vol. 32, Supplement 1, 1985 (1985) (0)
Identification of two distinct pathophysiologic forms of GERD (2000) (0)
CHOLECYSTOKININ (PANCREOZYMIN). 3. SYNTHESIS AND PROPERTIES OF AN ANALOG OF THE C-TERMINAL HEPTAPEPTIDE WITH SERINE SULFATE REPLACING TYROSINE SULFATE (1977) (0)
A Method to Adjust pH Values Obtained with Different pH Catheters: 113 (2008) (0)
THirteenth International Congress on Stomach Diseases (2007) (0)
Nocturnal Gastric Acidity and Nocturnal Esophageal Acidity Are Lower with Immediate-Release Omeprazole Than with Lansoprazole or Esomeprazole in GERD Patients Treated with a Proton Pump Inhibitor: 3 (2007) (0)
T1104 A Bayesian Method Using Esophageal Acid Exposure to Diagnose GERD (2010) (0)
Response (1993) (0)
Integrated acidity: a novel technique demonstrating synergy between low dose ranitidine and antacid for acid reduction and relief of meal-induced heartburn (2000) (0)
Demonstration of interactions between different affinity states of the pancreatic cholecystokinin (CCK) receptor (1995) (0)
CHOLECYSTOKININ (PANCREOZYMIN). 5. HORMONALLY ACTIVE DESAMINO DERIVATIVE OF TYR(SO3H)-MET-GLY-TRP-MET-ASP-PHE-NH2 (1980) (0)
Integrated acidity and heartburn severity determine timing of self-medication in postprandial heartburn (2000) (0)
Two different states of activation of cholecystokinin (CCK) receptors on pancreatic acinar cells (1980) (0)
Su370 USING CLINICAL TRIAL RESULTS TO REMOVE THE UNCERTAINTY IN TREATING AN INDIVIDUAL PATIENT WITH CIRRHOSIS AND THROMBOCYTOPENIA (2021) (0)
Role of cellular calcium in modulating the initial action of cholecystokinin on pancreatic acinar cells (1978) (0)
Title: GASTRIC ACIDITY IN DIFFERENT PHENOTYPES OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE Running Title: GASTRIC ACIDITY IN GERD (2023) (0)
Different mechanisms for carbachol induced down regulation of receptors for vasoactive intestinal peptide vip and cholecystokinin cck on pancreatic acini (1988) (0)
S1932 A Bayesian Method for Analyzing Relationships Between Esophageal Reflux Episodes and Symptoms (2009) (0)
The ability of operative endoscopic transillumina- Detection of Duodenal Gastrinomas by (1999) (0)
The specific binding of radioiodinated vasoactive intestinal octacosapeptide (VIP) on isolated pancreatic acinar cells from the guinea pig. (1975) (0)
SMALL INTESTINE/UNCLASSIFIED (2007) (0)
Action of exogenous cyclic nucleotides on enzyme secretion from pancreatic acinar cells: Discovery of a competitive inhibitor of cholecystokinin (1978) (0)
Reduced Nocturnal Gastric Alkalinization in Subjects with Gastroesophageal Reflux Disease: 123 (2009) (0)
The Internet and the Journal. (1995) (0)

This paper list is powered by the following services:

Jerry D. Gardner's Academic­Influence.com Rankings

Jerry D. Gardner's Degrees

Why Is Jerry D. Gardner Influential?

Jerry D. Gardner's Published Works

Published Works

Jerry D. Gardner's AcademicInfluence.com Rankings